PIM1 (Proviral Integration Site for Moloney Murine Leukemia Virus 1) is a constitutively active serine/threonine kinase belonging to the PIM family of kinases. Originally discovered as a proto-oncogene frequently activated by retroviral insertion in murine leukemia models, PIM1 has emerged as a critical regulator of neuronal survival, synaptic plasticity, and cognitive function. The kinase is widely expressed throughout the central nervous system, with particularly high levels in the hippocampus, cortex, and basal ganglia. PIM1 participates in diverse signaling pathways that control cell survival, metabolism, and plasticity, making it a significant player in both development and disease contexts. Unlike most kinases, PIM1 lacks a regulatory domain and maintains constitutive activity, allowing rapid signal transduction in response to cellular stress and neurotrophic factors. The protein has garnered considerable attention for its dual role in promoting neuronal survival while also contributing to pathological features of neurodegenerative diseases, particularly through its interactions with tau protein and alpha-synuclein.
PIM1 (Proviral Integration Site for Moloney Murine Leukemia Virus 1) is a constitutively active serine/threonine kinase belonging to the PIM family of kinases. Originally discovered as a proto-oncogene frequently activated by retroviral insertion in murine leukemia models, PIM1 has emerged as a critical regulator of neuronal survival, synaptic plasticity, and cognitive function. The kinase is widely expressed throughout the central nervous system, with particularly high levels in the hippocampus, cortex, and basal ganglia. PIM1 participates in diverse signaling pathways that control cell survival, metabolism, and plasticity, making it a significant player in both development and disease contexts. Unlike most kinases, PIM1 lacks a regulatory domain and maintains constitutive activity, allowing rapid signal transduction in response to cellular stress and neurotrophic factors. The protein has garnered considerable attention for its dual role in promoting neuronal survival while also contributing to pathological features of neurodegenerative diseases, particularly through its interactions with tau protein and alpha-synuclein.
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>Proviral Integration Site for Moloney Murine Leukemia Virus 1</td></tr>
<tr><th>Gene Symbol</th><td>[PIM1](/genes/pim1)</td></tr>
<tr><th>UniProt ID</th><td>[P11309](https://www.uniprot.org/uniprotkb/P11309/entry)</td></tr>
<tr><th>PDB Structures</th><td>1XJD, 2JSS, 2Y0N, 4ALU, 5DWR</td></tr>
<tr><th>Molecular Weight</th><td>34 kDa (313 aa)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, Nucleus</td></tr>
<tr><th>Brain Expression</th><td>High in hippocampus, cortex, striatum, cerebellum</td></tr>
<tr><th>Protein Family</th><td>PIM kinase family (PIM1, PIM2, PIM3)</td></tr>
<tr><th>Chromosome Location</th><td>6p21.1</td></tr>
</table>
</div>
PIM1 possesses a characteristic kinase domain architecture that distinguishes it from typical serine/threonine kinases. The protein contains:
Unlike typical kinases, PIM1 lacks:
PIM1 undergoes several regulatory modifications:
PIM1 promotes cell survival through phosphorylation of multiple pro-survival substrates:
PIM1 phosphorylates [BAD](/proteins/bad-protein) (Bcl-2-associated agonist of cell death) at serine 112, which disrupts the pro-apoptotic function of BAD by promoting its binding to 14-3-3 proteins and preventing it from inhibiting anti-apoptotic [Bcl-2](/proteins/bcl2-protein) family members. This pathway is particularly important in neurons, where BAD-mediated apoptosis contributes to neurodegeneration. The phosphorylation of BAD by PIM1 provides a critical survival signal that protects neurons from various apoptotic stimuli, including trophic factor withdrawal and oxidative stress[@fan2019].
PIM1 phosphorylates [FOXO1](/proteins/foxo1-protein) transcription factor, promoting its nuclear export and inactivation. Since FOXО transcription factors regulate expression of pro-apoptotic genes including BIM and PUMA, PIM1-mediated phosphorylation provides an additional survival mechanism. In neurons, this pathway helps maintain cellular homeostasis under stress conditions[@xu2019].
PIM1 regulates mitochondrial function through phosphorylation of key proteins involved in fission and fusion:
PIM1 plays a critical role in synaptic plasticity, the cellular basis of learning and memory:
PIM1 is upregulated during LTP induction and contributes to the molecular consolidation of synaptic changes. The kinase phosphorylates proteins involved in AMPA receptor trafficking and synaptic scaffolding, enhancing synaptic strength. Studies using PIM1 knockout mice show deficits in LTP and impaired spatial memory formation[@wang2022].
PIM1 regulates dendritic spine density and morphology through phosphorylation of cytoskeletal regulatory proteins. Loss of PIM1 leads to reduced spine density and abnormal spine shapes, while overexpression promotes spine formation. This function involves regulation of Rac1 and cofilin activity[@yang2022].
PIM1 interacts with [NMDA receptor](/proteins/nmda-receptor) subunits and modulates receptor trafficking and signaling. This interaction is important for calcium influx during synaptic activity, which triggers downstream plasticity mechanisms[@jacobson2022].
PIM1 is induced by neurotrophic factors including:
PIM1 can phosphorylate transcription factors and co-activators:
PIM1 has complex and multifaceted involvement in Alzheimer's disease pathogenesis:
PIM1 directly phosphorylates tau protein at multiple sites relevant to AD pathology. The kinase can phosphorylate tau at serine 262, a site within the microtubule-binding domain that disrupts tau-microtubule interaction and promotes aggregation. Additionally, PIM1 contributes to tau phosphorylation at other AD-relevant sites including serine 396 and threonine 231. This pathological phosphorylation promotes tau aggregation into neurofibrillary tangles and disrupts normal tau function in axonal transport[@chen2020].
PIM1 expression is altered in response to amyloid-beta exposure. Studies show that amyloid-beta oligomers induce PIM1 expression in neurons, and this upregulation appears to be a compensatory neuroprotective response. However, chronic elevation of PIM1 may contribute to tau pathology and other disease mechanisms. PIM1 also mediates some of the toxic effects of amyloid-beta through its effects on survival signaling and synaptic function[@hu2018].
PIM1 is involved in neuroinflammatory responses in AD. The kinase regulates microglial activation and cytokine production, contributing to the chronic neuroinflammation characteristic of AD. PIM1 expression in microglia is increased around amyloid plaques, where it may modulate the inflammatory microenvironment[@zhou2021].
Multiple studies have documented altered PIM1 expression in AD brain tissue. Immunohistochemical analyses show increased PIM1 in vulnerable brain regions including hippocampus and entorhinal cortex. This elevation correlates with disease severity and neuropathological burden. The cellular distribution shows PIM1 in both neurons and glia, with particularly high levels in neurons containing neurofibrillary tangles[@brown2019].
Given the involvement of PIM1 in multiple aspects of AD pathogenesis, the kinase represents a potential therapeutic target. However, the dual role of PIM1 in both promoting neuronal survival and contributing to pathology creates complexity for therapeutic targeting. Strategies under investigation include:
PIM1 involvement in Parkinson's disease centers on dopaminergic neuron survival and alpha-synuclein pathology:
PIM1 provides critical survival signals for dopaminergic neurons in the substantia nigra. The kinase is induced by GDNF and other neurotrophic factors that promote dopaminergic neuron survival. Loss of PIM1 in animal models exacerbates dopaminergic neuron loss, while overexpression provides neuroprotection. This suggests PIM1 as a potential therapeutic target for preserving dopaminergic neurons in PD[@liu2018].
PIM1 can phosphorylate alpha-synuclein at serine 129, a modification extensively studied in PD pathogenesis. While serine 129 phosphorylation is found in most Lewy bodies and may have complex effects on aggregation and toxicity, PIM1's contribution to this modification adds to the complex picture of alpha-synuclein pathology in PD[@liu2020].
PIM1 regulates autophagy, a cellular process critical for clearing damaged proteins and organelles. In PD, autophagy dysfunction contributes to alpha-synuclein accumulation. PIM1 can both promote and inhibit autophagy depending on context, making its net effect on protein clearance complex. Regulation of autophagy by PIM1 involves phosphorylation of key autophagy proteins and modulation of mTOR signaling[@chen2021].
PIM1 expression is altered in Huntington's disease models and may contribute to neuronal dysfunction. The kinase participates in mutant huntingtin toxicity pathways and could represent a therapeutic target.
PIM1 has been implicated in motor neuron survival in ALS. Studies show altered PIM1 expression in ALS models and human tissue, though the precise role remains to be clarified.
PIM1 provides neuroprotective effects in ischemic brain injury. Pre-conditioning paradigms that induce PIM1 expression lead to improved outcomes following stroke, suggesting PIM1 induction as a potential neuroprotective strategy.
While not directly relevant to neurodegeneration, PIM1 is well-characterized as an oncogene:
Several PIM1 inhibitors have been developed for oncological applications and are being evaluated for neurodegenerative diseases:
Therapeutic targeting of PIM1 for neurodegenerative diseases faces several challenges:
PIM1 promotes both neuronal survival (beneficial) and pathological processes (harmful). Selective modulation that preserves survival functions while reducing pathology represents a significant challenge.
Many PIM1 inhibitors have limited CNS penetration, necessitating development of brain-penetrant compounds for neurological applications.
Biomarkers to guide patient selection and monitor treatment response are needed for clinical development.
Beyond direct kinase inhibition, other strategies include: